A 12-month interim analysis of the AGILE Phase III extension study confirms the long-term safety and efficacy of twice-yearly ...
A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...
Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback